However, given the complexity of lipid metabolism, the precise molecular mechanisms under the dyslipidemic conditions have not been completely understood; few of the treatments with lipid-lowering ...

Lipoproteins, particularly low-density lipoprotein-like particles, including Lp(a), are causally involved in atherosclerosis. Our armamentarium to achieve intensive lipid-lowering has ... with newly ...

has shown that atherosclerosis is a dynamic, inflammatory process that is eminently modifiable. Support for this view comes from clinical trials of lipid lowering agents, particularly the “statins”, ...

Educating the general population on the safe and best use of lipid-lowering agents is imperative, given the widespread availability of such therapies. Whether or not you are in favor of the ...

Under the leadership of principal investigator Iftikhar J. Kullo, M.D., the Atherosclerosis and Lipid Genomics Laboratory focuses its research efforts on better understanding the genetics of ...

Atherosclerosis is a chronic ... a key enzyme in cholesterol synthesis — are the most widely used type of lipid-lowering medication. For each mmol/L reduction in LDL-C levels, statins provide ...

Lipid-lowering agents are medications designed to reduce cholesterol and triglyceride levels in the blood, thereby helping to prevent cardiovascular diseases. These agents include statins, fibrates, ...

Merck has a strong foothold in the atherosclerosis market with its zetimia (ezetimibe) and the recent development of promising therapies in combination with other lipid-lowering agents. The company’s ...

This study seeks to use Mendelian randomisation (MR) to assess the causal relationship between lipid traits and lipid-lowering drug targets and full-course DR (background DR, severe non-proliferative ...

LDL cholesterol level at entry had to be between 125 mg/dL and 210 mg/dL after a 4-10 week period to wash out any previous lipid-lowering agent effects. IVUS was obtained at 34 centers and ...